Madrigal: Phase 3 Development of Resmetirom, a liver directed thyroid hormone receptor (THR)-β agonist for the treatment of patients with NASH and significant liver fibrosis - ILC 2021
View
Immune-Mediated and Cholestatic Diseases
6
Intercept: Providing Better Care in PBC – understanding the evolving evidence - ILC 2021
View
Immune-Mediated and Cholestatic Diseases
6
Intercept: Providing Better Care in PBC – understanding the evolving evidence - ILC 2021
View
Immune-Mediated and Cholestatic Diseases
6
Intercept: Providing Better Care in PBC – understanding the evolving evidence - ILC 2021
View
Immune-Mediated and Cholestatic Diseases
6
Intercept: Providing Better Care in PBC – understanding the evolving evidence - ILC 2021
View
Immune-Mediated and Cholestatic Diseases
6
Intercept: Providing Better Care in PBC – understanding the evolving evidence - ILC 2021
View
Immune-Mediated and Cholestatic Diseases
6
Intercept: Providing Better Care in PBC – understanding the evolving evidence - ILC 2021
View
Viral Hepatitis
2
GSK: HBsAg clearance in chronic hepatitis B: How close is it? - ILC 2021
View
Viral Hepatitis
2
GSK: HBsAg clearance in chronic hepatitis B: How close is it? - ILC 2021
View
Cirrhosis & Complications
5
Grifols: Management of decompensated cirrhotic patient: is it time to look beyond? - ILC 2021
View
Cirrhosis & Complications
5
Grifols: Management of decompensated cirrhotic patient: is it time to look beyond? - ILC 2021
View
Cirrhosis & Complications
5
Grifols: Management of decompensated cirrhotic patient: is it time to look beyond? - ILC 2021
